M1 Kliniken AG: 11% EBIT Surge, EPS Hits €0.86

• M1 Kliniken AG reported an 11% growth in EBIT and achieved earnings per share of EUR 0.86 for the first nine months of 2025.
• Group revenue increased by 6.7% to EUR 274.3 million, with EBITDA rising by 9% to EUR 28.2 million.
• The Beauty segment was a key growth driver, with revenue up by 9.5% to EUR 77.8 million and EBIT increasing by 29.7% to EUR 21.1 million.
• The Trading segment saw a 6% increase in revenue to EUR 196.5 million, but EBIT decreased by 41.4% to EUR 3.4 million.
• M1 Kliniken AG's subsidiary, HAEMATO AG, signed an agreement to sell HAEMATO Pharm GmbH to the PHOENIX group, subject to antitrust approvals.
• M1 Kliniken AG plans to expand its clinic network and aims for a sustainable EBIT margin of at least 20% by 2029, positioning itself as a leading brand in aesthetic medicine.

The price of M1 Kliniken at the time of the news was 15,350EUR and was down -0,32 % compared with the previous day.
10 minutes after the article was published, the price was 15,560EUR this corresponds to a plus of +1,37 % since publication.

M1 Kliniken

+1,73 %

-3,08 %

+17,53 %

+26,65 %

+5,81 %

+143,66 %

+106,94 %

+253,47 %

ISIN:DE000A0STSQ8WKN:A0STSQ

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max